title: In-hospital initiation of secondary prevention is associated with improved vascular outcomes at 3 months.
abstract: BACKGROUND
  Although various in-hospital stroke quality improvement programs have been associated with high treatment rates at hospital discharge, there are few data on the impact of these programs on clinical outcomes. We evaluated the impact of the PROTECT (Preventing Recurrence Of Thromboembolic Events through Coordinated Treatment) program on short-term vascular risk.
  
  
  METHODS
  Prospective data collected after discharge for ischemic stroke or transient ischemic attack caused by presumed atherosclerotic mechanism from a PROTECT intervention hospital and a comparison community hospital, which used conventional care, were compared. The 3-month follow-up clinical outcome data were then evaluated and differences in outcome frequency data between the two hospital groups were analyzed using Fisher's exact test. Covariate adjusted comparisons of percent with a vascular event was computed via logistic regression methods.
  
  
  RESULTS
  A total of 224 patients met study criteria: 126 patients at a PROTECT hospital and 98 patients at a comparator hospital. The 3-month postdischarge data were available for 78 patients at PROTECT hospital versus 65 control patients. Patients at a PROTECT hospital were more likely to be younger, be current smokers, and not have a history of atrial fibrillation. At 3 months, there was a covariate-adjusted difference in the intervention-hospital group versus the control-hospital group with regard to the incidence of a vascular event (transient ischemic attack, stroke, or myocardial infarction), 8.4% versus 22% (P = .036).
  
  
  CONCLUSIONS
  Compared with conventional care, PROTECT was associated with better 3-month vascular outcomes after stroke hospitalization. Further study is needed to confirm the potential favorable impact of stroke quality improvement programs on clinical outcomes.
authors.affiliation: Department of Neurology, University of California at Los Angeles School of Medicine, Los Angeles, California 90095, USA.
authors.forename: Abdul
authors.initials: A
authors.lastname: Rahiman
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Saver
authors.forename: Verna
authors.initials: V
authors.lastname: Porter
authors.forename: William
authors.initials: W
authors.lastname: Buxton
authors.forename: Norma
authors.initials: N
authors.lastname: McNair
authors.forename: Tannaz
authors.initials: T
authors.lastname: Razinia
authors.forename: Bruce
authors.initials: B
authors.lastname: Ovbiagele
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data* / Q000639:trends; D006801:Humans; D015994:Incidence; D002546:Ischemic Attack, Transient / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D017063:Outcome Assessment, Health Care; D010351:Patient Discharge / Q000706:statistics & numerical data; D011446:Prospective Studies; D011785:Quality Assurance, Health Care; D011787:Quality of Health Care / Q000706:statistics & numerical data* / Q000639:trends; D055502:Secondary Prevention; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D016896:Treatment Outcome